MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sales and
maturities of marketable...
$261,971K
Proceeds from the
purchase of common stock...
$549K
Proceeds from the
exercise of stock options
$267K
Net cash provided by
(used in) investing...
$125,446K
Net cash provided by
financing activities
$816K
Canceled cashflow
$136,525K
Net (decrease)
increase in cash, cash...
-$6,205K
Canceled cashflow
$126,262K
Stock-based compensation
expense
$14,787K
Non-cash lease expense
$4,871K
Depreciation
$4,060K
Prepaid expenses and
other assets
-$3,617K
Accounts payable
$1,017K
Related party
collaboration receivable
-$525K
Loss on disposal of
fixed assets
-$141K
Purchases of marketable
securities
$133,929K
Purchases of property and
equipment
$2,596K
Net cash (used in)
provided by operating...
-$132,467K
Canceled cashflow
$29,018K
Net (loss) income
-$119,721K
Deferred revenue
-$28,807K
Operating lease
liabilities
-$7,227K
Amortization of premiums and
discounts on marketable...
$2,973K
Accrued expenses
-$2,500K
Accounts receivable
$257K
Back
Back
Cash Flow
source: myfinsight.com
Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. (VYGR)